The Breast Cancer Market is expected to grow at an 8.8% CAGR during the forecast period for 2024-2031.
Breast cancer start when cells in the breast begin to grow out of control. These cells form tumour that can often see on an x-ray. Breast cancer is the most common cancer among women, after skin cancer and second leading cause of cancer death in women after lung cancer. Breast cancer is broadly classified into two include non-invasive and invasive breast cancer. Ductal carcinoma in situ (DCIS) is non-invasive cancer of milk duct cells. Invasive breast cancer is divided into two types, invasive ductal carcinoma, and invasive lobular carcinoma. Invasive ductal carcinoma, also called infiltrating ductal carcinoma and it consists of about 50-75 percent of all breast cancer. Invasive breast cancer that spreads to other parts of the body is called metastatic breast cancer. All non-invasive and invasive breast cancer tested for hormone (oestrogen and progesterone) receptors. The hormone receptor-positive cancer can be treated with hormone therapy such as tamoxifen and an aromatase inhibitor. Breast cancer is the most common cancer in women both in developed and developing countries. Breast cancer is most common in U.S. women, with about 252,710 new cases diagnosed and 40,610 die in 2017. Almost 81% of breast cancer are diagnosed among women age 50 years and older, and 89% of breast cancer deaths occur in this age group.
Diagnosis of breast cancer can be done with physical examination, clinical breast examination (CBE), mammogram, ultrasound exam, MRI (magnetic resonance imaging), blood test, and biopsy. There are different types of treatment for patients with breast cancer include surgery, chemotherapy, hormone therapy, and targeted therapy. Surgery such as breast-conserving surgery, total mastectomy, modified radical mastectomy. Systemic chemotherapy is used in the treatment of breast cancer includes capecitabine (Xeloda), docetaxel (Taxotere), eribulin (Halaven), gemcitabine (Gemzar), paclitaxel (Taxol), vinorelbine (Navelbine), and others. Hormone therapy with a luteinizing hormone-releasing hormone (LHRH) agonist is given to premenopausal who have been diagnosed with hormone receptor-positive breast cancer. Targeted therapy used in breast cancer include trastuzumab, pertuzumab, ado-trastuzumab emtansine, lapatinib, neratinib, palbociclib, ribociclib and abemaciclib.
The diagnosis, staging, and treatment of patients with breast cancer require multidisciplinary care in an acute hospital setting. In the U.S. Genentech Access to Care Foundation (GATCF) scheme helping patients to have access to Herceptin. Genentech Access to Care Foundation (GATCF) scheme helps people who don’t have health insurance coverage and those who have health insurance but have trouble paying for Herceptin. Additionally, Medicare insurance policies pay the fee for a clinical breast examination (CBE) once every two years for women at average risk of breast cancer.
|
Report Attribute |
Specifications |
|
Growth Rate CAGR |
CAGR of 8.8% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Treatment |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Novartis AG, Genentech, Inc., GlaxoSmithKline plc, Mylan Pharmaceuticals Inc., Teva Pharmaceuticals USA, Inc., AstraZeneca, Apotex Corp. Breckenridge Pharmaceutical, Inc., Pfizer Inc., Alvogen, and others |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Breast Cancer Market Snapshot
Chapter 4. Global Breast Cancer Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Treatment Estimates & Trend Analysis
5.1. By Treatment & Market Share, 2023 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Treatment:
5.2.1. Chemotherapy
5.2.2. Targeted Therapy
5.2.3. Hormonal Therapy
5.2.4. Surgery
Chapter 6. Breast Cancer Market Segmentation 2: Regional Estimates & Trend Analysis
6.1. North America
6.1.1. North America Breast Cancer Market revenue (US$ Million) estimates and forecasts By Treatment, 2024 - 2031
6.1.2. North America Breast Cancer Market revenue (US$ Million) estimates and forecasts by country, 2024 - 2031
6.2. Europe
6.2.1. Europe Breast Cancer Market revenue (US$ Million) By Treatment, 2024 - 2031
6.2.2. Europe Breast Cancer Market revenue (US$ Million) by country, 2024 - 2031
6.3. Asia Pacific
6.3.1. Asia Pacific Breast Cancer Market revenue (US$ Million) By Treatment, 2024 - 2031
6.3.2. Asia Pacific Breast Cancer Market revenue (US$ Million) by country, 2024 - 2031
6.4. Latin America
6.4.1. Latin America Breast Cancer Market revenue (US$ Million) By Treatment, 2024 - 2031
6.4.2. Latin America Breast Cancer Market revenue (US$ Million) by country, 2024 - 2031
6.5. Middle East & Africa
6.5.1. Middle East & Africa Breast Cancer Market revenue (US$ Million) By Treatment, 2024 - 2031
6.5.2. Middle East & Africa Breast Cancer Market revenue (US$ Million) by country, 2024 - 2031
Chapter 7. Competitive Landscape
7.1. Major Mergers and Acquisitions/Strategic Alliances
7.2. Company Profiles
7.2.1. Novartis AG
7.2.2. Genentech, Inc
7.2.3. GlaxoSmithKline plc
7.2.4. Mylan Pharmaceuticals Inc
7.2.5. Teva Pharmaceuticals USA, Inc
7.2.6. AstraZeneca
7.2.7. Apotex Corp
7.2.8. Breckenridge Pharmaceutical, Inc
7.2.9. Pfizer Inc.
7.2.10. Alvogen
7.2.11. Other Key Players
Global Breast Cancer Market Segmentation
Global Breast Cancer Market Outlook By Treatment
Global Breast Cancer Market Outlook By Region
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
